Contraindications
- Pregnancy and breastfeeding
- Women of childbearing potential not using effective contraception
- Children (under 16 years)
- Long-term treatment of chronic conditions (not recommended)
Dosing: Adult
- Adjuvant treatment of painful muscle contractures in acute spinal conditions (16 years and older): Oral: up to 8 mg every 12 hours for at most 7 days. Intramuscular: up to 4 mg every 12 hours for at most 5 days
Dosing: Altered kidney function
Thiocolchicoside is a muscle relaxant whose metabolite (3-demethylthiocolchicine) caused aneuploidy in preclinical studies, so the European Medicines Agency restricted it in 2014 to short courses in adults and adolescents 16 years and older. The European review gives no kidney-impairment dosing. It has no US FDA label.
Kidney function measure: The EMA review does not address kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Oral: maximum 8 mg every 12 hours for no more than 7 consecutive days. Intramuscular: maximum 4 mg every 12 hours for up to 5 days (EMA 2014).
- CrCl 30–59 mL/min
- The EMA review gives no kidney dosing, and no kidney pharmacokinetic data were retrieved. Use with caution and specialist judgment.
- CrCl 15–29 mL/min
- The EMA review gives no kidney dosing, and no kidney pharmacokinetic data were retrieved. Use with caution and specialist judgment.
- CrCl <15 mL/min (not on dialysis)
- The EMA review gives no kidney dosing, and no kidney pharmacokinetic data were retrieved. Use with caution and specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated.
- Monitoring Do not exceed dose or duration limits (oral 8 mg every 12 hours for up to 7 days; IM 4 mg every 12 hours for up to 5 days); aneuploidy risk from a metabolite. Pregnancy status: contraindicated in pregnancy, breastfeeding and in women of childbearing potential without effective contraception. Do not exceed the dose or duration limits (EMA 2014).
Children (kidney dosing)
- eGFR ≥60
- Not for children under 16; no pediatric kidney data.
- eGFR 30–59
- Not for children under 16; no pediatric kidney data.
- eGFR 15–29
- Not for children under 16; no pediatric kidney data.
- eGFR <15 (not on dialysis)
- Not for children under 16; no pediatric kidney data.
- Hemodialysis (intermittent)
- Not for children under 16; no pediatric kidney data.
- Peritoneal dialysis
- Not for children under 16; no pediatric kidney data.
- CRRT
- Not for children under 16; no pediatric kidney data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: EMA product information (January 17, 2014). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Adults and adolescents 16 years and older only (EMA 2014).
- Usual dose
- 16 years and older: adult limits.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Orodispersible tablet: 8 mg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Thiocolchicoside as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Thiozz-8Thiocolchicoside | 8 mg Orodispersible TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Ipca Laboratories Ltd.India | Blue Global (FZE) | DR-XY48339 | Sep 6, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Adverse reactions
Serious
- Aneuploidy risk from a metabolite (preclinical): possible teratogenicity, miscarriage, impaired male fertility
Monitoring parameters
- Do not exceed dose or duration limits (oral 8 mg every 12 hours for up to 7 days; IM 4 mg every 12 hours for up to 5 days); aneuploidy risk from a metabolite. Pregnancy status: contraindicated in pregnancy, breastfeeding and in women of childbearing potential without effective contraception. Do not exceed the dose or duration limits (EMA 2014). Kidney
- Dose and duration limits (aneuploidy risk)
- Pregnancy status and contraception
Pharmacokinetics
Key PK parameters
| Active metabolites | 3-demethylthiocolchicine (SL59.0955), linked to aneuploidy |
|---|---|
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- European Medicines Agency. Thiocolchicoside Article 31 referral (2014) [EMA product information, January 17, 2014; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/referrals/thiocolchicoside-containing-medicines
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- European Medicines Agency. (2014). Thiocolchicoside-containing medicines: Article 31 referral (Commission decision January 17, 2014; EMA/706409/2013). https://www.ema.europa.eu/en/medicines/human/referrals/thiocolchicoside-containing-medicines
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .